Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TAF1 | P21675 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532058 | 1.00 | TNF (0.35) | TNFRIPK1AHRMEN1KMT2A | |
| SCHEMBL4824761 | 0.89 | HTR2C (0.40) | TNFRIPK1AHRHTR2AHTR2C | |
| SCHEMBL4822429 | 0.76 | ADRA2A (0.39) | TNFRIPK1AHRPTK2BTK | |
| SCHEMBL6197080 | 0.71 | MAPT (0.39) | RIPK1MEN1KMT2APTK2BTK | |
| SCHEMBL1978270 | 0.70 | MEN1 (0.41) | AHRMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL6798065 | 0.69 | MAOA (0.33) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL7494644 | 0.69 | NQO2 (0.42) | TNFRIPK1AHRMEN1KMT2A | |
| SCHEMBL1374474 | 0.67 | TNF (0.54) | TNFRIPK1AHRMEN1KMT2A | |
| SCHEMBL29591462 | 0.67 | TNF (0.54) | TNFRIPK1AHRMEN1KMT2A | |
| SCHEMBL1536405 | 0.67 | PARP1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436004-B1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-10730884-B2 | Substituted indole compound derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730884-B2 | Substituted indole compound derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190276467-A1 | Substituted indole compound derivatives as dengue viral replication inhibitors | JANSSEN-CILAG (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190276467-A1 | Substituted indole compound derivatives as dengue viral replication inhibitors | JANSSEN-CILAG (FR) | 2019-09-12 | — | — | US | disclosed |
| EP-3436004-A1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017167952-A1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017167952-A1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-29 | — | — | US | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| US-7166632-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166613-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | disclosed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| US-5633276-A | MELATONIN SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | TNF 4349/4885RIPK1 2414/4885AHR 72/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | TNF 4349/4885RIPK1 2414/4885AHR 72/4885 |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | HTR2C, HTR2A, HTR1A | TNF 4345/4885RIPK1 2425/4885AHR 72/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | TNF 4349/4885RIPK1 2414/4885AHR 72/4885 |
| US-20190276467-A1 | Substituted indole compound derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | TNF 1054/4885RIPK1 1608/4885AHR 236/4885 |
| US-10730884-B2 | Substituted indole compound derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | TNF 1054/4885RIPK1 1608/4885AHR 236/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | TNF 4349/4885RIPK1 2414/4885AHR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.